With a new manufacturing deal in place, Crossject is on course to launch the first product based on its needle-free injector system next year.
Grünenthal has selected Patheon as its preferred development partner for its anti-abuse formulation platform INTAC, based on Hot Melt Extrusion (HME) technology.
US compounder Pharmedium has recalled sterile drugs made with contaminated saline supplied by Pfizer's Hospira unit.
A Massachusetts-based police department has published contact and salary details of Big Pharma CEOs in an effort to force industry to help manage opiate addiction.
Opioid addiction drug Suboxone lost market share in 2014 according to newly independent Indivior, whose management says it is not intimidated by increased competition.
The implementation of track and trace will drive the outsourcing of drug packaging and UDG Healthcare is well-placed to benefit, according to a UK broking firm.
An anti-addiction group has called for a change in leadership at the US FDA following the approval of Zohydro and other high-dose opioid analgesics.
Almac’s subsidiary Galen has licensed UK sales and marketing rights to an emergency pain drug nicknamed the “green whistle” from Australian firm Medical Developments International (MVP).
Canadian drugmaker Intellipharmaceutics has developed a kill-switch formulation it says will prevent drug misuse and accidental overdoses.
Elite Pharma has decided to manufacture its developmental anti-abuse pain drug in-house despite offers from several CMOs interested in the contract.
The Center for Lawful Access and Abuse Deterrence (CLAAD) is working with the US Food and Drug Administration (FDA) on legislation for abuse-deterrent technology in opioids, its directors tell in-PharmaTechnologist.com.
Janssen Pharmaceuticals is prepared for Tramadol's reclassification by the US Drug Enforcement Administration (DEA) and says the supply of its versions of the opioid analgesic will not be interrupted.
The US FDA has granted Priority Review Designation to Purdue Pharma’s hydrocodone bitartrate tablet which has abuse-deterrent technology.
Acura has reacquired the rights to its opioid abuse-deterrent technology from Pfizer and is looking for pharma partners to relaunch its oxycodone HCL drug Oxecta.
Anticipated demand for the drug Exparel has led to a contract win for Patheon, though NDA holder Pacira says it will maintain control of all aspects of the manufacturing process.
US-based BioDelivery Sciences International (BDSI) has selected Quintiles to provide a range of services to support the expected launch of Bunavail (buprenorphine and naloxone buccal film), a maintenance treatment for opioid dependence.
European regulators have been accused of making “no attempt” to counter misuse of prescription drugs in comparison with North American efforts to reformulate and restrict addictive drugs, according to a Canadian firm testing the abuse potential of medicines.
CSL Biotherapies and Hospira are both separately recalling drugs due to contamination and syringe overfilling respectively.
Manufacturing of ONSOLIS is all go, says BioDelivery Sciences
Production of BioDelivery Sciences International’s (BDSI) chronic pain treating drug, ONSOLIS, has resumed after a temporary voluntary shut down at contract manufacturers, Aveva Drug Delivery Systems.
Anti-addiction drug delivery implant outperforms placebo
In Phase III trials an implanted drug delivery device administering a steady low-dose of buprenorphine reduced illicit opioid use compared to placebo.
US FDA OKs film formulation of opioid-dependance drug
Drug delivery company Monosol Rx and partner Reckitt Benckiser Pharmaceuticals have received US Food and Drug Administration (FDA) clearance to market a sublingual film formulation of the opioid dependence treatment Suboxone.
Endo to buy Penwest for Opana ER tech
Endo Pharmaceuticals will pay $168m (€127.7m) for drug delivery tech and formulations firm Penwest Pharmaceuticals in bid to expand pain portfolio.
Penwest Q2 revs up, but job cuts likely
Penwest Pharmaceuticals raises guidance citing Opana ER royalties, deals and patent settlements as Q2 highlights; but warns that job cuts likely under cost cutting plan.
Durect and King sign long-term Remoxy excipient supply deal
Chemicals firm Durect will supply drugmaker King Pharmaceuticals with two excipients used in the manufacture of the candidate anti-abuse painkiller Remoxy in an agreement signed last week.
Aoxing’s pain drug plant gets GMP OK
China Aoxing Pharmaceutical, a specialist developer of pain management drugs, has received GMP accreditation for the new tablet production and packaging plant it has set up in Shijiazhuang.
Alpharma buoyed by panel decision on Embeda
Alpharma moved a step closer to bringing its morphine product Embeda to market after a US Food and Drug Administration advisory panel agreed that it is less susceptible to abuse than other opioid analgesic products.
Cody unveils homogenous method for morphine derivatives
API maker Cody Laboratories is targeting the lucrative analgesic and pain management markets with a new process that improves the efficiency of hydromorphone and hydrocodone manufacture.
Drug delivery news in brief
in-PharmaTechnologist’s periodic round up of developments in the field of drug delivery includes BioDelivery initiating Phase I studies, success for Titan and a novel use for Viagra.
Abuse-resistant oxycodone primed for clinical trials
IntelliPharmaCeutics is ready to move into full-scale clinical
trials with a once-daily oral formulation of oxycodone based on the
company's ReXista abuse- and alcohol-resistant technology.
BDSI takes on full ownership of BEMA drug delivery tech
BioDelivery Sciences International (BDSI) has acquired the US
rights to the BEMA oral adhesive disc drug delivery technology for
$3m, with a further $4m to be paid at a later date.
Intranasal NSAID a first for pain relief
The first ever non-steroidal anti-inflammatory drug (NSAID) to be
delivered via the nose has been developed, and its makers are
heralding it as "an important breakthrough in treating
Trials halted after bowel drug linked to heart risk
GlaxoSmithKline (GSK) and Adolor have halted development of an
innovative drug designed to improve pain relief, amid concerns that
the drug could cause heart problems.
PainCeptor Pharma adds patents to pain portfolio
PainCeptor Pharma has announced it has been awarded a series of
patents for its drug development programs that focus on pain
management whilst avoiding the many detrimental side effects
associated with current pain drugs.
European Authorities recommend IONSYS approval
European Authorities recommended the first needle-free system for
acute postoperative pain for approval this week, which allows
patient-controlled delivery of fentanyl in post-operative pain
Lollipop painkiller goes sugar free
Sugar is a useful excipient for use in medications because of its
ability to mask bitter tastes, but its use in drugs intended for
chronic use, or which reside in the mouth for an extended period,
raises the risk of dental caries.
Abuse-resistant opioid clears Phase III trial
A novel painkiller in development at Pain Therapeutics - based on a
technology that both improves dosing and prevents drug abuse - has
done well in a Phase III clinical trial.
Vernalis buys intranasal opioid company
UK biotechnology company Ionix Pharmaceuticals is gearing up for
acquisition by Vernalis in a share-based deal valuing Ionix at
around £12.5 million (€18.2m).
Drug delivery firms join forces
BioDelivery Sciences International has entered into a definitive
agreement to acquire all of the capital stock of fellow drug
delivery firm Arius Pharmaceuticals.
US biotech cleared for drug delivery deal
US biotechnology company Cephalon says that the US Federal Trade
Commission has approved its $385 million acquisition of CIMA Labs,
nearly a year after it outbid aaiPharma for the drug delivery
SkyePharma lifted by US approval
UK drug delivery specialist SkyePharma received another welcome
boost yesterday with the news that its new formulation of morphine
had been approved in the US.
CIMA ditches aaiPharma for Cephalon
Cephalon is to acquire CIMA Laboratories, best known for its
dissolve-on-the-tongue tablet technology, for $515 million (€449m)
Formulation answer to drug abuse
A new formulation technology developed by Rohm and Haas has the
potential to do away with the problem of prescription drug abuse
and make medicines safer in overdose. In-Pharmatechnologist.com
discussed this and other applications...